Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2012-11-07 Report Publication Anno…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its second participation to Actionaria, a forum dedicated to meeting with individual investors, on November 23 & 24, in Paris
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that Innate Pharma will be meeting with retail investors at the 'Actionaria' forum on specific dates. It details the CEO's participation in several conferences/debates during the event and provides contact information for receiving invitations. This type of communication, focused on engaging with individual shareholders and announcing participation in investor-focused events, aligns best with general investor relations activities. Since it is not a formal regulatory filing (like 10-K, ER, or IR), nor a specific announcement about dividends (DIV), management changes (MANG), or voting results (DVA), it falls under general investor communication. The closest fit among the provided options for an announcement aimed at engaging investors outside of formal reporting cycles is often categorized under Investor Presentation (IP) if it were a presentation deck, or more broadly as a general investor relations communication. However, given the context of meeting retail investors at a specific forum, it is an announcement about investor engagement. Since there is no specific code for 'Investor Event Announcement', and it is not a formal presentation (IP) or a formal report announcement (RPA), it is best classified as a general Regulatory Filing (RNS) as a catch-all for investor relations news that doesn't fit the highly specific categories, or potentially IP if interpreted as an announcement *about* investor engagement materials/meetings. Given the focus on meeting retail investors and the nature of the announcement (not a formal presentation deck itself), RNS is the most appropriate fallback for non-standard investor news, although it strongly relates to investor engagement. Re-evaluating the options: It is an announcement about meeting investors, which is a form of investor relations activity. It is not a formal presentation (IP). It is not a report publication (RPA). Therefore, RNS (Regulatory Filings/Miscellaneous) is the most suitable category for this specific type of investor relations press release.
2012-11-07 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce qu’un essai clinique de Phase I sponsorisé par Bristol-Myers Squibb pour IPH2102/BMS-986015 a été publié sur le site du NIH clinicaltrial
Regulatory Filings Classification · 97% confidence The document is titled as an 'ANNONCE' (Announcement) dated October 30, 2012, detailing the initiation of a Phase I clinical trial sponsored by Bristol-Myers Squibb for a drug candidate (IPH2102/BMS-986015). It describes the trial objectives, design, and context regarding the drug development partnership. This type of announcement, which communicates a specific operational or clinical development update rather than comprehensive financial results (like 10-K or ER) or a formal regulatory filing document itself, fits best under the general category of corporate news or regulatory updates. Since it is an announcement about a clinical trial progress, it is not a standard financial report. Given the options, it is a specific corporate announcement. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is a specific operational update. While it could potentially fall under RNS (Regulatory Filings) as a catch-all, the content is highly specific to clinical development and partnership news. However, in the context of standard SEC/financial filings, announcements of clinical trial progress are often disseminated via press release, which aligns closely with the nature of an 'Earnings Release' (ER) if it were financial, or a general 'Regulatory Filing' (RNS). Since it is a press release announcing a clinical trial update, and there is no specific code for 'Clinical Trial Update', RNS (Regulatory Filings) serves as the most appropriate general category for non-financial, material corporate news releases that don't fit elsewhere, or it could be considered a type of Investor Information. Given the options, and recognizing this is a press release announcing a material development (clinical trial initiation), RNS is the safest general classification for non-standard corporate announcements.
2012-10-30 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)today announces that a Phase I trial sponsored by Bristol-Myers Squibb was published on the NIH website ClinicalTrials.gov for IPH2102/BMS-986015 a
Regulatory Filings Classification · 96% confidence The document is a press release dated October 30, 2012, announcing that a clinical trial involving IPH2102/BMS-986015, sponsored by Bristol-Myers Squibb, was published on ClinicalTrials.gov and is recruiting. It details the purpose, design, and background of the trial and the compounds involved. This type of announcement, detailing operational updates, partnerships, and clinical trial progress, is characteristic of an Investor Presentation (IP) or a general press release related to R&D activities. Since it is not a formal financial report (like 10-K or IR), nor a specific announcement of management change (MANG), dividend (DIV), or financing (CAP), it best fits the Investor Presentation (IP) category, which often includes strategic and operational updates for investors, or potentially Regulatory Filings (RNS) if it were a mandatory disclosure. Given the detailed scientific and partnership information aimed at investors, IP is a strong fit, although it lacks the typical slide deck format of a formal IP. However, it is clearly an announcement intended for investors about a significant operational development (clinical trial update). It is not a Report Publication Announcement (RPA) because it is the primary announcement of the news, not just a notice that a report is available. I will classify it as an Investor Presentation (IP) due to its content focus on R&D progress and partnership details.
2012-10-30 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses résultats semestriels au 30 juin 2012
Earnings Release Classification · 100% confidence The document is an 'Earnings Release' (ER) from Innate Pharma. It provides a summary of the semi-annual financial results for the period ending June 30, 2012, including key financial highlights (revenue, net loss, cash position), operational updates, and a summary table of financial statements. While it contains financial data, it is structured as a press release announcing these results to the market, rather than a full statutory interim report. It fits the definition of an Earnings Release perfectly. H1 2012
2012-09-06 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces today its financial results for the first half of 2012
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2012, containing detailed IFRS consolidated financial statements, analysis of revenue, operating expenses, and business trends. It is not merely an announcement, as it provides substantive financial data and management commentary. Therefore, it is classified as an Interim/Quarterly Report. H1 2012
2012-09-06 English
Rapport financier semestriel d'Innate Pharma au 30 juin 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport financier semestriel au 30 juin 2012' (Half-year financial report as of June 30, 2012). It contains comprehensive financial statements, including income statements, balance sheets, and detailed management analysis of financial results for the six-month period. It is not a short announcement or a certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2012
2012-09-06 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.